Major Depressive Disorder – Global Drug Forecast and Market Analysis to 2029
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
The drug sales for Major Depressive Disorder (MDD) were valued at $3.97 billion across the eight major pharmaceutical markets (8MM) in 2019. The market is projected to grow at a CAGR of more than 7% during the forecast period. The US market makes up the majority of total global sales due to the large MDD prevalent population, combined with the high price of medication in the country.
MDD is one of the most common psychiatric diseases worldwide characterized by single or recurrent major depressive episodes (MDEs). MDD is only diagnosed if an MDE is not better explained by a psychotic disorder such as schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, or other psychotic disorder, and if there is no history of hypomania or mania. The term unipolar depressive disorder is often used to distinguish MDD from depressive episodes that occur in conjunction with manic episodes, known as bipolar disorder.
MDD market overview
For more insights on this report, download a free report sample
What are the market dynamics in the MDD market?
The major drivers of growth in the MDD market during the forecast period include the launch of eight new pipeline products throughout the 8MM which will have significantly higher costs of therapy when compared with the cost of the most commonly used MDD treatments that have high generic availability. Furthermore, the number of 12-month total prevalent cases of MDD is expected to increase during the forecast period in the 8MM. MDD has a multifaceted and varied etiology and remains poorly understood. The MDD market is crowded and highly competitive, with a significant number of the marketed products now available as inexpensive generics. The MDD market is in a dynamic phase with the patent expiries of some of the top-selling products.
What is the country-level outlook of the MDD market?The MDD market in the US was the largest market in the 8MM. Atypical antipsychotics hold the greatest MDD market share in the US. The main driver behind its success is the high price of drugs in this class. In 2019, the highest-selling drug was Otsuka/Lundbeck’s Rexulti, followed by Lundbeck/Takeda’s multimodal antidepressant Trintellix. Among the five European markets (5EU), namely France, Germany, Italy, Spain, and the UK, Germany has the largest proportion of sales within the market. This is so as the country has a larger population and therefore a higher number of prevalent cases compared to the remaining European markets. France had the smallest market of the 5EU, due to low drug prices. In terms of drug sales, Lundbeck’s Brintellix is the highest-selling drug. Japan has the second largest market in the 8MM. The SNRIs held the greatest MDD market share in Japan, in 2019. This is due to limited generic availability in this class. The highest-selling drug was Cymbalta. Furthermore, the drug class of other antidepressants will demonstrate the greatest growth across the Japanese MDD market. In 2019, the atypical antipsychotics hold the greatest MDD market share in Canada, closely followed by the SNRIs. The highest-selling drug was Otsuka/Lundbeck’s Rexulti, followed by Eli Lilly’s Cymbalta.
The MDD market in the US was the largest market in the 8MM. Atypical antipsychotics hold the greatest MDD market share in the US. The main driver behind its success is the high price of drugs in this class. In 2019, the highest-selling drug was Otsuka/Lundbeck’s Rexulti, followed by Lundbeck/Takeda’s multimodal antidepressant Trintellix. Among the five European markets (5EU), namely France, Germany, Italy, Spain, and the UK, Germany has the largest proportion of sales within the market. This is so as the country has a larger population and therefore a higher number of prevalent cases compared to the remaining European markets. France had the smallest market of the 5EU, due to low drug prices. In terms of drug sales, Lundbeck’s Brintellix is the highest-selling drug.
Japan has the second largest market in the 8MM. The SNRIs held the greatest MDD market share in Japan, in 2019. This is due to limited generic availability in this class. The highest-selling drug was Cymbalta. Furthermore, the drug class of other antidepressants will demonstrate the greatest growth across the Japanese MDD market. In 2019, the atypical antipsychotics hold the greatest MDD market share in Canada, closely followed by the SNRIs. The highest-selling drug was Otsuka/Lundbeck’s Rexulti, followed by Eli Lilly’s Cymbalta.
MDD market, by key countries
For more country insights, download a free report sample
Who are the key players in the MDD market?
Some of the key players in the MDD market are Axsome Therapeutics, Relmada Therapeutics, AbbVie, Lundbeck, Takeda, Otsuka, Allergan, Janssen, Pfizer, Sage Therapeutics, Eli Lilly, Intra-Cellular Therapies, and Biogen.
Market report scope
Market size (Year – 2019) | $3.97 billion |
Growth rate | CAGR of >7% |
Forecast period | 2019-2029 |
Key players | Axsome Therapeutics, Relmada Therapeutics, AbbVie, Lundbeck, Takeda, Otsuka, Allergan, Janssen, Pfizer, Sage Therapeutics, Eli Lilly, Intra-Cellular Therapies, and Biogen |
This report provides:
- Overview of Major Depressive Disorder, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
- Annualized Major Depressive Disorder therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in three patient segments (Mild, Moderate, and Severe), and forecast from 2019 to 2029.
- Key topics including strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications for the Major Depressive Disorder therapeutics market.
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for Major Depressive Disorder therapy. The most promising candidates in Phase III development are profiled.
- Analysis of the current and future market competition in the global Major Depressive Disorder therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
Key Highlights
- Significant growth is expected in the MDD market from 2019 to 2029.
- GlobalData’s anticipate that eight late stage pipeline drugs will launch over the forecast period. These are expected to be the main driver of growth in the MDD market across the 8MM.
- GlobalData expects Axsome Therapeutics’ AXS-05 to become the top-selling drug in the MDD market with sales of $1.32B in 2029.
- Established and emerging players are aiming to develop antidepressants and adjunctive therapies with a broad range of different, novel MOAs that will enable them to compete in a highly crowded market space.
- Opportunities are expected for pharmaceutical companies to develop drugs that target treatment-resistant patients, as well as products that improve remission rates and prevent relapses.
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Major Depressive Disorder therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Major Depressive Disorder therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Relmada Therapeutics
AbbVie
Lundbeck
Takeda
Otsuka
Allergan
Janssen
Pfizer
Sage Therapeutics
Eli Lilly
Intra-Cellular Therapies
Biogen
Luye Pharma
GSK
Merck
AstraZeneca
Bristol-Myers Squibb
Click Therapeutics
Kao Health
Veeva Systems
Fabre-Kramer Pharmaceuticals
Table of Contents
Table
Figures
Frequently asked questions
-
What was the MDD market size in 2019?
The drug sales for MDD were valued at $3.97 billion in 2019.
-
What is the MDD market growth rate?
The MDD market is projected to grow at a CAGR of more than 7% during the forecast period.
-
Who are the key players in the MDD market?
Some of the key players in the MDD market are Axsome Therapeutics, Relmada Therapeutics, AbbVie, Lundbeck, Takeda, Otsuka, Allergan, Janssen, Pfizer, Sage Therapeutics, Eli Lilly, Intra-Cellular Therapies, and Biogen.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.